Oxazepam Tablets manufacturers & suppliers

Oxazepam Tablets

Form: Tablets

Strength: 10 mg, 15 mg, 30 mg

Reference Brands: Sobril®(EU)

Category: Antipsychotropic Drugs

Oxazepam tablets are FDA-approved in the United States for the management of anxiety disorders and for the short-term relief of anxiety symptoms, including anxiety associated with depression and acute alcohol withdrawal. As a Schedule IV controlled substance, U.S. regulations require CNS depressant labeling, abuse potential warnings, and compliance with GMP standards for manufacturing. In the European Union, oxazepam is approved under various brand names through national marketing authorizations, often for anxiety and insomnia. EU regulations include Risk Management Plans (RMPs) and mandatory pharmacovigilance. For dossier-ready Oxazepam tablet supply and B2B sourcing, visit Pharmatradz.com.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Risperidone Long-Acting Injection

Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg vials/syringes

Form: Long-Acting Injection

Reference Brands: Risperdal Consta(US &EU)

View Details
Zuclopenthixol Ong-Acting Im Injection (Depot)

Strength: 200 mg/mL, 500 mg/mL

Form: Long-acting IM Injection (Depot)

Reference Brands: Clopixol Depot®(US)

View Details
Zuclopenthixol Short-Acting Intramuscular Injection

Strength: 50 mg/mL

Form: Short-acting Intramuscular Injection

Reference Brands: Clopixol-Acuphase®

View Details
Zuclopenthixol Tablets

Strength: 10 mg, 25 mg, 40 mg

Form: Oral Tablets

Reference Brands: Clopixol®(EU)

View Details

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

We use cookies to ensure you get the best experience. Learn more